Search research articles
Contact Us
Filters
Showing results (231-240 of 248) with videos related to
Page
of 25
Sort By:
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
February 26, 2024
Depression follow-up monitoring with the PHQ-9: an open cluster-randomised controlled trial
Tony Kendrick, Christopher Dowrick, Glyn Lewis, et al.
JMIR Research Protocols
|
November 20, 2020
The Active Brains Digital Intervention to Reduce Cognitive Decline in Older Adults: Protocol for a Feasibility Randomized Controlled Trial
Kirsten Ailsa Smith, Katherine Bradbury, Rosie Essery, et al.
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Frontiers in Public Health
|
October 7, 2022
Parallel randomized controlled feasibility trials of the "Active Brains" digital intervention to protect cognitive health in adults aged 60-85
Rosie Essery, Sebastien Pollet, Katherine Bradbury, et al.
Clinical Pharmacology and Therapeutics
|
October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
JAMA Network Open
|
June 24, 2024
Internet and Telephone Support for Discontinuing Long-Term Antidepressants: The REDUCE Cluster Randomized Trial
Tony Kendrick, Beth Stuart, Hannah Bowers, et al.
The Journal of Antimicrobial Chemotherapy
|
August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 248) with videos related to
Sort By:
Page
of 25
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
February 26, 2024
Depression follow-up monitoring with the PHQ-9: an open cluster-randomised controlled trial
Tony Kendrick, Christopher Dowrick, Glyn Lewis, et al.
JMIR Research Protocols
|
November 20, 2020
The Active Brains Digital Intervention to Reduce Cognitive Decline in Older Adults: Protocol for a Feasibility Randomized Controlled Trial
Kirsten Ailsa Smith, Katherine Bradbury, Rosie Essery, et al.
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Frontiers in Public Health
|
October 7, 2022
Parallel randomized controlled feasibility trials of the "Active Brains" digital intervention to protect cognitive health in adults aged 60-85
Rosie Essery, Sebastien Pollet, Katherine Bradbury, et al.
Clinical Pharmacology and Therapeutics
|
October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
JAMA Network Open
|
June 24, 2024
Internet and Telephone Support for Discontinuing Long-Term Antidepressants: The REDUCE Cluster Randomized Trial
Tony Kendrick, Beth Stuart, Hannah Bowers, et al.
The Journal of Antimicrobial Chemotherapy
|
August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Page
of 25